Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

The study included: * A screening period for 21 days * Randomization at baseline (Treatment was initiated with 5 days of randomization) * A treatment period with 14-day study treatment cycles until a study withdrawal criterion was met * A follow-up period up to 60 days after the end of treatment Withdrawal criteria that led to treatment discontinuation were: * The participant or their legally authorized representative requested to withdraw * In the investigator's opinion, continuation of the study would be detrimental to the participant's well being, due to reasons such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations. * A specific request by the Sponsor * Participant had intercurrent illness that prevented further administration of study treatment * Participant had more than 2 aflibercept dose reductions * Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of pre-existing angina * Participant had radiographic evidence of intestinal obstruction (e.g., dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (e.g., presence of extraluminal gas) requiring surgical intervention * Participant was lost to follow-up After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later.